WO2011110842A3 - Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome - Google Patents

Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome Download PDF

Info

Publication number
WO2011110842A3
WO2011110842A3 PCT/GB2011/050454 GB2011050454W WO2011110842A3 WO 2011110842 A3 WO2011110842 A3 WO 2011110842A3 GB 2011050454 W GB2011050454 W GB 2011050454W WO 2011110842 A3 WO2011110842 A3 WO 2011110842A3
Authority
WO
WIPO (PCT)
Prior art keywords
glucose metabolism
birt
hogg
treatment
inhibitors
Prior art date
Application number
PCT/GB2011/050454
Other languages
French (fr)
Other versions
WO2011110842A2 (en
Inventor
Andrew Tee
Keith Baar
Original Assignee
Myrovlytis Technology Ventures Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myrovlytis Technology Ventures Limited filed Critical Myrovlytis Technology Ventures Limited
Priority to EP11709454A priority Critical patent/EP2544678A2/en
Priority to GB1218050.1A priority patent/GB2491539A/en
Publication of WO2011110842A2 publication Critical patent/WO2011110842A2/en
Publication of WO2011110842A3 publication Critical patent/WO2011110842A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A composition comprising an inhibitor of glucose metabolism for use in the treatment of Birt-Hogg-Dubé syndrome. The inhibitor of glucose metabolism may be a glycolytic inhibitor. The inhibitor of glucose metabolism may be an inhibitor of pyruvate metabolism. Suitable inhibitors of glucose metabolism include 2-deoxy-D- glucose or a pharmaceutically acceptable salt or solvate thereof or oxamate or a pharmaceutically acceptable salt or solvate thereof.
PCT/GB2011/050454 2010-03-09 2011-03-08 Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome WO2011110842A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP11709454A EP2544678A2 (en) 2010-03-09 2011-03-08 Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dubé syndrome
GB1218050.1A GB2491539A (en) 2010-03-09 2011-03-08 Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1003894.1 2010-03-09
GB1003894A GB2478556A (en) 2010-03-09 2010-03-09 A composition for use in the treatment of Birt-Hogg-Dubô sydrome

Publications (2)

Publication Number Publication Date
WO2011110842A2 WO2011110842A2 (en) 2011-09-15
WO2011110842A3 true WO2011110842A3 (en) 2012-05-10

Family

ID=42136701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/050454 WO2011110842A2 (en) 2010-03-09 2011-03-08 Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome

Country Status (3)

Country Link
EP (1) EP2544678A2 (en)
GB (2) GB2478556A (en)
WO (1) WO2011110842A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021007499A1 (en) * 2019-07-11 2021-01-14 Emory University Combination therapies for managing cancer
WO2021251842A1 (en) * 2020-06-08 2021-12-16 Qatar Foundation For Education, Science And Community Development Targeting of lactate dehydrogenase c, methods of preparing same, and methods of using same in combination with anti-cancer treatments

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062604A2 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
WO2004064734A2 (en) * 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
JP2010520289A (en) * 2007-03-07 2010-06-10 アブラクシス バイオサイエンス， エルエルシー Nanoparticles containing rapamycin and albumin as anticancer agents
KR20110090911A (en) * 2008-10-31 2011-08-10 노파르티스 아게 Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062604A2 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
WO2004064734A2 (en) * 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
H PELICANO ET AL: "Glycolysis inhibition for anticancer treatment", ONCOGENE, vol. 25, no. 34, 7 August 2006 (2006-08-07), pages 4633 - 4646, XP055009657, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1209597 *
JACQUELINE VUKY ET AL: "Phase II trial of imatinib (Gleevec(R)) in patients with metastatic renal cell carcinoma", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 24, no. 1, 1 January 2006 (2006-01-01), pages 85 - 88, XP019206130, ISSN: 1573-0646, DOI: 10.1007/S10637-005-4543-Z *
W. MARSTON LINEHAN ET AL: "Molecular Diagnosis and Therapy of Kidney Cancer*", ANNUAL REVIEW OF MEDICINE, vol. 61, no. 1, 1 February 2010 (2010-02-01), pages 329 - 343, XP055021613, ISSN: 0066-4219, DOI: 10.1146/annurev.med.042808.171650 *
YANG ET AL: "The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dube gene pathway", CANCER GENETICS AND CYTOGENETICS, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 180, no. 2, 16 January 2008 (2008-01-16), pages 100 - 109, XP022422140, ISSN: 0165-4608, DOI: 10.1016/J.CANCERGENCYTO.2007.10.010 *

Also Published As

Publication number Publication date
GB2478556A (en) 2011-09-14
WO2011110842A2 (en) 2011-09-15
GB2491539A (en) 2012-12-05
GB201003894D0 (en) 2010-04-21
EP2544678A2 (en) 2013-01-16
GB201218050D0 (en) 2012-11-21

Similar Documents

Publication Publication Date Title
IL260560B (en) A sulfonyl-amino pyrimidinyl-amino benzamide compound for use as a medicament in a method for the treatment of cancer in a mammal
WO2009134389A9 (en) An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
IL223889B (en) Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
IL221372A0 (en) 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients
IL210494A (en) Organic compounds as smo inhibitors and pharmaceutical compositions comprising them for use in the treatment of cancer
AU2012214029A8 (en) Rorgammat inhibitors
IL232515A0 (en) Nadph oxidase 4 inhibitors and pharmaceutical compositions containing the same
PL2646425T3 (en) Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
WO2009117482A8 (en) Mtor inhibitor salt forms
HK1125831A1 (en) Fat accumulation inhibitor for the treatment of metabolic syndrome
IL199829A0 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
EP1982724A4 (en) Therapeutic agent for metabolic syndrome and food containing the therapeutic agent
EP2395980A4 (en) Compositions and methods for treating post-operative pain using bupivacaine and an anti-inflammatory agent
PL2756764T3 (en) Sweetener composition for preventing and improving obesity, containing glycolysis inhibitor ingredient
IL202307A (en) Multikinase inhibitors for use in the preparation of pharmaceutical compositions for the treatment of various cancers
EP2019098A4 (en) Suppressor of expression of mcp-1, and ameliorating agent for inflammatory disease, pharmaceutical, supplement, food, beverage or food additive using the suppressor
EP2322175A4 (en) Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof
ZA201206898B (en) Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferatiive disorders
EP2056830A4 (en) Compositions useful especially for treatment or prevention of metabolic syndrome
WO2012064396A3 (en) Novel ezrin inhibitors and methods of making and using
HK1158108A1 (en) Therapeutic or prophylactic agent for generalized pain syndrome
WO2011110842A3 (en) Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome
MX2013014398A (en) Heterocyclic sulfonamide derivatives.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11709454

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 1218050

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20110308

WWE Wipo information: entry into national phase

Ref document number: 1218050.1

Country of ref document: GB

Ref document number: 8785/DELNP/2012

Country of ref document: IN

Ref document number: 2011709454

Country of ref document: EP